BR112020003865A8 - Composições farmacêuticas compreendendo sepiapterina e seus usos - Google Patents

Composições farmacêuticas compreendendo sepiapterina e seus usos

Info

Publication number
BR112020003865A8
BR112020003865A8 BR112020003865A BR112020003865A BR112020003865A8 BR 112020003865 A8 BR112020003865 A8 BR 112020003865A8 BR 112020003865 A BR112020003865 A BR 112020003865A BR 112020003865 A BR112020003865 A BR 112020003865A BR 112020003865 A8 BR112020003865 A8 BR 112020003865A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions including
sepiapterin
including sepiapterin
tetrahydrobiopterin
Prior art date
Application number
BR112020003865A
Other languages
English (en)
Other versions
BR112020003865A2 (pt
Inventor
E Levy Daniel
Original Assignee
Censa Pharmaceuticals Inc
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc, Ptc Therapeutics Mp Inc filed Critical Censa Pharmaceuticals Inc
Publication of BR112020003865A2 publication Critical patent/BR112020003865A2/pt
Publication of BR112020003865A8 publication Critical patent/BR112020003865A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A presente invenção caracteriza composições farmacêuticas incluindo sepiapterina, ou um sal farmaceuticamente aceitável e/ou co-cristal do mesmo, e métodos para o tratamento de distúrbios relacionados à tetra-hidrobiopterina (por exemplo, deficiência de tetra-hidrobiopterina ou fenilcetonuria) com tais composições.
BR112020003865A 2017-09-01 2018-09-04 Composições farmacêuticas compreendendo sepiapterina e seus usos BR112020003865A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762553603P 2017-09-01 2017-09-01
US62/553,603 2017-09-01
US201862678069P 2018-05-30 2018-05-30
US62/678.069 2018-05-30
PCT/US2018/049359 WO2019046849A1 (en) 2017-09-01 2018-09-04 PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Publications (2)

Publication Number Publication Date
BR112020003865A2 BR112020003865A2 (pt) 2020-09-08
BR112020003865A8 true BR112020003865A8 (pt) 2022-08-16

Family

ID=65526057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003865A BR112020003865A8 (pt) 2017-09-01 2018-09-04 Composições farmacêuticas compreendendo sepiapterina e seus usos

Country Status (8)

Country Link
US (2) US11752154B2 (pt)
EP (1) EP3675863A4 (pt)
JP (2) JP2020532535A (pt)
CN (1) CN111491635A (pt)
BR (1) BR112020003865A8 (pt)
CA (1) CA3073957A1 (pt)
MX (1) MX2020002271A (pt)
WO (1) WO2019046849A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
CN116903624A (zh) 2016-11-29 2023-10-20 Ptc医疗Mp公司 墨蝶呤及其盐的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
US20210161901A1 (en) * 2018-05-30 2021-06-03 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
EP3807279A4 (en) * 2018-05-30 2022-04-06 PTC Therapeutics MP, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
CN112703002A (zh) * 2018-05-30 2021-04-23 Ptc医疗Mp公司 增加墨蝶呤血浆暴露的方法
US20220273661A1 (en) 2019-08-05 2022-09-01 Ptc Therapeutics Mp, Inc. Use of sepiapterin and metabolites thereof to treat radiation exposure
MX2022003585A (es) * 2019-09-25 2022-04-19 Ptc Therapeutics Mp Inc Metodos para tratar hiperfenilalaninemia.
WO2021150983A1 (en) 2020-01-24 2021-07-29 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
EP4291196A1 (en) 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating covid-19 with sepiapterin
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
IL311716A (en) 2021-09-29 2024-05-01 Ptc Therapeutics Inc Pharmaceutical compositions of Spiafetrin

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
AU727445B2 (en) 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
RU2434870C2 (ru) 2003-11-17 2011-11-27 Мерк Эпрова Аг Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
EP1776364A2 (en) 2003-11-17 2007-04-25 BioMarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
DK1877370T3 (da) 2005-04-28 2009-05-11 Shiratori Pharm Fremgangsmåde til fremstilling af hydrazon-derivater
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
EP2139485B1 (en) 2007-04-11 2012-10-17 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
PT2262790T (pt) 2008-03-10 2017-07-18 Takeda Pharmaceuticals Co Cristal de composto de benzimidazole
PL2309983T3 (pl) * 2008-08-12 2019-09-30 Orpha Swiss Gmbh Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
IN2012DN01453A (pt) 2009-08-20 2015-06-05 Novartis Ag
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
RU2017134002A (ru) 2011-03-01 2019-02-07 Дифарма С.А. Стабильные композиции тетрагидробиоптерина
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9181254B2 (en) 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
PT2926805T (pt) * 2014-03-31 2016-07-15 Vasopharm Gmbh Composições farmacêuticas sólidas que contêm derivados de biopterina e utilizações dessas composições
US20190167598A1 (en) * 2016-07-29 2019-06-06 Dipharma S.A. A novel treatment regimen involving sapropterin dihydrochloride
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
CN116903624A (zh) * 2016-11-29 2023-10-20 Ptc医疗Mp公司 墨蝶呤及其盐的多晶型物
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
EP3807279A4 (en) 2018-05-30 2022-04-06 PTC Therapeutics MP, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
CN112703002A (zh) 2018-05-30 2021-04-23 Ptc医疗Mp公司 增加墨蝶呤血浆暴露的方法
US20210161901A1 (en) 2018-05-30 2021-06-03 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
US20220273661A1 (en) 2019-08-05 2022-09-01 Ptc Therapeutics Mp, Inc. Use of sepiapterin and metabolites thereof to treat radiation exposure
MX2022003585A (es) 2019-09-25 2022-04-19 Ptc Therapeutics Mp Inc Metodos para tratar hiperfenilalaninemia.

Also Published As

Publication number Publication date
EP3675863A4 (en) 2021-01-27
JP2023116556A (ja) 2023-08-22
CA3073957A1 (en) 2019-03-07
MX2020002271A (es) 2020-10-05
BR112020003865A2 (pt) 2020-09-08
US20200061070A1 (en) 2020-02-27
EP3675863A1 (en) 2020-07-08
CN111491635A (zh) 2020-08-04
US20240100054A1 (en) 2024-03-28
US11752154B2 (en) 2023-09-12
JP2020532535A (ja) 2020-11-12
WO2019046849A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
BR112020003865A8 (pt) Composições farmacêuticas compreendendo sepiapterina e seus usos
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019010222A8 (pt) Polimorfos de sepiapterina e sais dos mesmos
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12017501958B1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
SV2018005753A (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
BR112018067922A2 (pt) compostos antibacterianos e seus usos
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112017004393A2 (pt) formulações de anticorpo
CL2021000930A1 (es) Piridazinas novedosas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
BR112018009413A2 (pt) formulação oral sólida e método para preparar a formulação oral sólida
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
MX2018009948A (es) Formulaciones de oritavancina.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: CENSA PHARMACEUTICALS INC. (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870220040149, DE 09/05/2022, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: PTC THERAPEUTICS MP, INC. (US)

B25G Requested change of headquarter approved

Owner name: PTC THERAPEUTICS MP, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]